Beta blockers Or Placebo for Primary Prophylaxis of oesophageal varices

- NIHR Health Technology Assessment commissioned grant call
- Application supported closely by KCL Clinical Trials Unit
- £2.3 million award – King’s College Hospital

**CHIEF INVESTIGATOR:** Vishal Patel

**CHIEF SCIENTIFIC INVESTIGATOR:** Mark McPhail

**TRIAL MANAGER:** Kieran Brack
• **Trial Design:** Multi-centre, phase IV, triple blinded (participant, investigator, analyst), prospective RCT

• **Purpose:** To determine if carvedilol reduces rate of variceal haemorrhage (VH) in patients with cirrhosis and small oesophageal varices (OV)

• **Primary objective(s):** To determine the *clinical and cost effectiveness* of the reduction in VH in patients treated with carvedilol vs placebo after 3 years.

• **Secondary objectives:** all-cause mortality, increase in OV size, hospitalisation with decompensation, MELD score increase, development of overt hepatic encephalopathy (HE), ascites, jaundice, renal impairment, HCC, myocardial infarction, liver transplantation. NSBB optimisation in 1o care

• **Target population & setting:** 1,200 cirrhotic patients with small OV to be recruited across 20 UK NHS sites, each f/u for 3 years
**Primary Endpoints**

1. Time to first variceal haemorrhage
2. Cost-utility of NSBB over trial follow up to 3 years.

**Secondary Endpoints**

From baseline to 3 years:

1. Estimation of the 1 and 3-year variceal bleed rate by allocation, and associated number needed to treat
2. Progression to medium/large varices requiring clinical intervention
3. Composite of progression in variceal size or bleeding as per (1) and (2) by 3 years
4. Clinical decompensation (new ascites, SBP, new hepatic encephalopathy)
5. Progression in Child Pugh grade
6. Progression in MELD score (continuous)
7. Survival (Overall, liver related, cardiovascular related)
8. Quality of life, EQ-5D-5L
9. Healthcare usage
BOPPP: Inclusion criteria

✓ **Cirrhosis and portal hypertension** defined by any 2 of:
  ✓ Characteristic **clinical** examination findings; one or more of:
    • Characteristic liver function tests
    • Haematological panel
    • Coagulation profile abnormalities
  ✓ Characteristic **radiological** findings; one or more of:
    • Heterogeneous liver with irregular contour; Splenomegaly
    • Ascites; Varices
    • Recanalised umbilical vein
  ✓ **FibroScan** liver stiffness measurement >15 kPa without other explanation
  ✓ Fibrosis score > stage 4 on **liver biopsy**

✓ **Small OV diagnosed within 3 months** defined as:
  • \( \leq 5 \) mm in diameter, or
  • disappear on moderate insufflation

✓ Not received a beta-blocker in the last week
✓ 18 years and over
✓ Capacity to provide informed consent
BOPPP: Exclusion criteria

❌ Non-cirrhotic portal hypertension
❌ Current or history of medium/large OV
❌ Isolated gastric, duodenal, rectal varices with or without recent bleeding
❌ Red signs during gastroscopy, previous variceal haemorrhage
❌ Known intolerance / contraindications to beta-blocker use
❌ Already receiving a beta-blocker that cannot be discontinued
❌ Child Pugh C cirrhosis
❌ Graft cirrhosis post liver transplantation
❌ Evidence of active malignancy without curative therapy planned
❌ Pregnant or lactating women
❌ Women of child bearing potential not willing to use adequate contraception
❌ CTIMP in last 3 months
Patients with cirrhosis assessed for eligibility following detection of small oesophageal varices at gastroscopy (n = 3,600)

Randomised (n = 1,200)

Excluded (n = 2,400)
- Not meeting inclusion criteria
- Meeting exclusion criteria
- Declined participation

Enrolment

Allocation
- Allocated to intervention with NSBB (Carvedilol) (n=600)
- Allocated to control (Placebo) (n=600)

Follow-Up
- Week one (up-titration)
- Week Six (AEs only)
- Clinic visits every six months: M6, M12, M18, M24, M30, and M36

Telephone Call
- Week six (AEs only)

Follow-Up
- Clinic visits every six months: M6, M12, M18, M24, M30, and M36

All patients without a variceal bleed followed up at study conclusion

Analysis
- All patients without a bleed followed up at study conclusion
## BOPPP: Schedule of Events

<table>
<thead>
<tr>
<th>Trial procedures</th>
<th>Pre-screening</th>
<th>Screening Visit</th>
<th>Baseline</th>
<th>Week 1 (3 days)</th>
<th>Week 6 (2 weeks)</th>
<th>Month 6 (6 weeks)</th>
<th>Month 12 (6 weeks)</th>
<th>Month 18 (6 weeks)</th>
<th>Month 24 (6 weeks)</th>
<th>Month 30 (6 weeks)</th>
<th>Month 36 (6 weeks)</th>
<th>Atorvastatin bleeding</th>
<th>At trial completion (Vancitos)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility criteria</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomisation</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics*</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical History*</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Targeted physical exam*</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight / Height*</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vital signs (BP/HR)*</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TE/APRI*</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FBC*</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INR*</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver, Renal and Bone profile*</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IMP dispensing</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Commence IMP</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dose - titration</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCC surveillance US*</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastroscopy*</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conmeds*</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse Events**</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>QoL questionnaire</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health Care Usage</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adherence to IMP</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nurse telephone call</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Pilot 1:
Recruitment and Retention

- 12 months following opening of recruitment

- Go / No Go criteria:
  - 8 sites opened
  - 1 patient recruited at each
  - Randomised 80+
  - Retention rate 70%
Pilot 2: Variceal bleed rate

- Month 30 (June 2022)
- Using Control arm only
- Bleed rate must be ≥4%
- Sample size 360

Go / No Go criteria:
- ≥4% continue as planned
- 2-4% consider trial length or sample size
- <2% stop trial
1) Recruitment barriers / enablers:

• Trial participants that consent, and those that decline:
  – Screening & Consent
  – Trial schedule
  – Acceptability of randomisation
  – Benefits and risks of participation

• Endoscopists, research nurses, pharmacists at sites:
  – Recruitment procedures
  – Support strategies to optimise recruitment

• Variety of sites to reflect UK wide experience and views

2) Treatment implementation post trial
BOPPP: Timelines

- REC meeting ☑ REC approval ☑
- MHRA submission ☑ CTA approval ☑
- NIHR portfolio adoption ☑ HRA approval ☑
- IMP and placebo manufacture ☑ - shipping to sites May 2019
- Trial Steering and Data Monitoring Committees ☑ Joint meeting 24/04/19
- Site opening: June 2019 -> April 2020
- Pan-London Investigator Meeting: 24th May 2019
- First patient first visit June 2019
- Pilot phase 1: Recruitment and Retention - March 2020
- Pilot phase 2: Estimation of variceal bleeding rate - June 2022
36 sites expressed interest – all REC approved

All provided feasibility information:
- Experience
- Resource: local support, Clinical Research Network (CRN) support
- Estimated patient numbers (screening → eligible → consent)
- Local clinical pathway compatibility
- Identifiable issues and challenges
- Most sites are CALIBRE +ive

Ranked, TMG division into two waves
- Wave 1 – opening May 2019 to April 2020
- Wave 2 – contingency sites (replace closed / unopened)

Wave 1 officially invited February 2019
- R&D and Pharmacy packs provided March 2019
- Internal approvals underway
## BOPPP: Site opening

<table>
<thead>
<tr>
<th></th>
<th>Month 5</th>
<th>Month 6</th>
<th>Month 7</th>
<th>Month 8</th>
<th>Month 9</th>
<th>Month 10</th>
<th>Month 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>KCH &amp; PRUH</td>
<td></td>
<td></td>
<td>July '19</td>
<td>Aug '19</td>
<td>Sept '19</td>
<td>Oct '19</td>
<td>Nov '19</td>
</tr>
<tr>
<td>Frimley</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>St George's</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Portsmouth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brighton</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bristol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nottingham</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Derby</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plymouth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Devon &amp; Exeter</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belfast</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imperial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Royal Free</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Birmingham</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Newcastle</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cambridge</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bradford</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glasgow</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liverpool</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
- NSBB vs EBL
- 2,600 pts with medium-large OV
- 30 UK sites
- 6 year study

- NSBB vs placebo
- 1,200 pts with small OV
- 20 UK sites
- 6 year study

- CALIBRE and BOPPP are complimentary, not competitive

- If BOPPP pts progress: unblind: *if placebo* → *SoC* → for CALIBRE

- Joint 1 page information sheet for both trials
<table>
<thead>
<tr>
<th>Hospital及Trust名称</th>
<th>负责人</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barts Health NHS Trust</td>
<td>Dr Vikram Sharma</td>
</tr>
<tr>
<td>Royal Victoria Hospital, Belfast</td>
<td>Dr Roger McCorry</td>
</tr>
<tr>
<td>University Hospitals Birmingham</td>
<td>Dr Dhiraj Tripathi</td>
</tr>
<tr>
<td>Bradford Royal Infirmary</td>
<td>Dr Sulleman Moreea</td>
</tr>
<tr>
<td>Brighton and Sussex University Hospitals</td>
<td>Dr Khaleel Jamil</td>
</tr>
<tr>
<td>North Bristol NHS Foundation Trust</td>
<td>Dr Zeino Zeino</td>
</tr>
<tr>
<td>Addenbrookes Hospital, Cambridge</td>
<td>Dr Jo Leithead</td>
</tr>
<tr>
<td>Royal Devon and Exeter Hospital</td>
<td>Dr Andrew Austin</td>
</tr>
<tr>
<td>Devon &amp; Exteter</td>
<td>Dr Ben Hudson</td>
</tr>
<tr>
<td>Frimley Park Hospital</td>
<td>Dr Kuldeep Cheent</td>
</tr>
<tr>
<td>Glasgow Royal Infirmary</td>
<td>Prof Adrian Stanley</td>
</tr>
<tr>
<td>St Mary's Hospital, Imperial College Healthcare</td>
<td>Dr Ameet Dhar</td>
</tr>
<tr>
<td>King's College Hospital, London</td>
<td>Dr Mark McPhail</td>
</tr>
<tr>
<td>Royal Liverpool University Hospital</td>
<td>Dr Imran Patanwala</td>
</tr>
<tr>
<td>Newcastle</td>
<td>Dr Steven Masson</td>
</tr>
<tr>
<td>Nottingham University Hospitals</td>
<td>Dr Stephen Ryder</td>
</tr>
<tr>
<td>Derriford Hospital, Plymouth</td>
<td>Prof Matthew Cramp</td>
</tr>
<tr>
<td>Queen Alexandra Hospital, Portsmouth</td>
<td>Dr Andrew Fowell</td>
</tr>
<tr>
<td>Princess Royal University Hospital</td>
<td>Dr Mayur Kumar</td>
</tr>
<tr>
<td>Royal Free Hospital, London</td>
<td>Dr Jennifer Ryan</td>
</tr>
<tr>
<td>St George's Hospital, London</td>
<td>Dr Sarah Hughes</td>
</tr>
</tbody>
</table>
Acknowledgements

Kieran Brack
Joe Montabello
Brian Hogan
Ane Zamalloa
Vernie Ramalingam
Andrew Ayers
Adam Hossen-Mamode
Liver Research Team
Rahman Ahmed
Iain Macdougall

Mark McPhail
Ben Carter
Hassan Jaffari
Mark Pennington
Vanessa Lawrence
Clair Le Boutillier
Caroline Murphy
Angela Cape

BOPPP PPI Group:
Neville Hargrave
Morwenna Orton
Elaine Mullins
Peter Walsh

Oluwadamilola Otiko
Helen Critchley
Jackie Pullen

Oliver Gupta
Rima Gupta

Brighton and Sussex University Hospitals
NHS Trust

Sumita Verma

St George’s Healthcare
NHS Trust

Daniel Forton

NIHR Clinical Research Network South London

Chris Ward

An Academic Health Sciences Centre for London
Pioneering better health for all